[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,835,216
  • Shares Outstanding, K 171,215
  • Annual Sales, $ 1,072 M
  • Annual Income, $ 391,000 K
  • EBIT $ 105 M
  • EBITDA $ 111 M
  • 60-Month Beta 0.86
  • Price/Sales 3.60
  • Price/Cash Flow 25.43
  • Price/Book 3.09

Options Overview Details

View History
  • Implied Volatility 45.75% (+7.72%)
  • Historical Volatility 36.84%
  • IV Percentile 29%
  • IV Rank 17.79%
  • IV High 98.54% on 01/09/26
  • IV Low 34.32% on 12/30/25
  • Expected Move (DTE 6) 2.55 (11.38%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 61
  • Volume Avg (30-Day) 306
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 14,863
  • Open Int (30-Day) 11,665
  • Expected Range 19.85 to 24.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.08
  • Number of Estimates 9
  • High Estimate $0.18
  • Low Estimate $-0.01
  • Prior Year $0.16
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.96 +6.87%
on 04/13/26
23.07 -2.90%
on 05/06/26
-0.16 (-0.71%)
since 04/08/26
3-Month
19.89 +12.62%
on 03/19/26
25.36 -11.67%
on 02/27/26
-1.16 (-4.92%)
since 02/06/26
52-Week
16.76 +33.68%
on 05/09/25
28.35 -20.99%
on 12/23/25
+5.47 (+32.31%)
since 05/08/25

Most Recent Stories

More News
Acadia: Q1 Earnings Snapshot

Acadia: Q1 Earnings Snapshot

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

- First quarter DAYBUE ® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway - First quarter...

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals Reports Tuesday With Rett Syndrome Revenue Still Under the Microscope

Barchart Research What to Expect from ACAD Earnings ACAD Generated May 5, 2026 Current Price $22.35 EPS Estimate $$0.04 Consensus Rating Moderate Buy Average Move 7.83% Acadia Pharmaceuticals Reports Tuesday...

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons...

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference ...

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting,...

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome...

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. ...

ACAD : 22.40 (-0.71%)
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company’s Audit Committee...

ACAD : 22.40 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 23.43
2nd Resistance Point 23.17
1st Resistance Point 22.78
Last Price 22.40
1st Support Level 22.14
2nd Support Level 21.88
3rd Support Level 21.49

See More

52-Week High 28.35
Fibonacci 61.8% 23.92
Fibonacci 50% 22.55
Last Price 22.40
Fibonacci 38.2% 21.19
52-Week Low 16.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.